Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd

₹ 1,947 3.55%
28 Mar - close price
About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Key Points

Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

  • Market Cap 32,977 Cr.
  • Current Price 1,947
  • High / Low 2,650 / 1,227
  • Stock P/E 51.9
  • Book Value 91.4
  • Dividend Yield 1.64 %
  • ROCE 36.0 %
  • ROE 26.5 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 45.9%
  • Company has been maintaining a healthy dividend payout of 107%

Cons

  • Stock is trading at 21.3 times its book value
  • The company has delivered a poor sales growth of 2.29% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
793 738 702 916 808 792 729 906 799 782 738 953 805
611 583 570 662 611 618 582 649 571 615 597 667 587
Operating Profit 182 155 132 254 197 173 148 257 228 167 141 287 218
OPM % 23% 21% 19% 28% 24% 22% 20% 28% 29% 21% 19% 30% 27%
42 -79 46 30 5 1,322 31 22 12 38 54 28 -135
Interest 1 1 1 0 1 0 1 0 0 1 0 0 0
Depreciation 18 18 18 17 18 15 16 16 16 17 16 18 17
Profit before tax 205 58 159 266 183 1,480 162 262 224 187 179 297 65
Tax % 23% 78% 24% 24% 18% 18% 27% 26% 27% 30% 27% 27% 30%
157 13 120 203 150 1,218 119 194 164 131 131 216 45
EPS in Rs 9.29 0.75 7.11 11.96 8.83 71.89 7.01 11.43 9.68 7.76 7.71 12.72 2.69
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Dec 2011 Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
2,376 2,626 2,546 3,288 2,826 2,903 2,872 3,129 3,225 2,920 3,218 3,216 3,279
1,593 1,811 2,024 2,660 2,349 2,482 2,361 2,522 2,566 2,323 2,462 2,417 2,466
Operating Profit 782 815 522 627 477 421 511 606 658 598 756 799 812
OPM % 33% 31% 20% 19% 17% 14% 18% 19% 20% 20% 23% 25% 25%
-163 49 227 147 125 118 69 106 -247 8 1,402 104 -14
Interest 0 0 0 0 0 0 0 1 6 4 2 2 2
Depreciation 20 18 20 25 25 27 38 49 83 79 68 66 69
Profit before tax 599 847 729 749 576 511 542 664 322 524 2,087 835 728
Tax % 28% 32% 31% 37% 35% 34% 35% 36% 66% 32% 19% 27%
431 577 502 472 375 337 352 425 110 358 1,691 608 523
EPS in Rs 25.42 34.08 29.63 27.84 22.11 19.88 20.78 25.11 6.50 21.11 99.79 35.88 30.88
Dividend Payout % 89% 73% 84% 112% 113% 75% 84% 80% 616% 142% 90% 89%
Compounded Sales Growth
10 Years: 2%
5 Years: 2%
3 Years: 0%
TTM: 2%
Compounded Profit Growth
10 Years: -1%
5 Years: 11%
3 Years: 44%
TTM: 47%
Stock Price CAGR
10 Years: 4%
5 Years: 8%
3 Years: 11%
1 Year: 53%
Return on Equity
10 Years: 27%
5 Years: 33%
3 Years: 46%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Dec 2011 Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 85 85 85 85 85 85 85 169 169 169 169 169 169
Reserves 1,835 1,925 1,932 1,767 2,120 1,944 1,995 1,973 1,671 1,328 2,508 1,584 1,378
5 5 4 3 2 2 1 1 0 35 20 16 21
1,086 1,075 1,129 1,382 864 991 1,884 1,766 1,291 1,565 1,925 1,559 1,697
Total Liabilities 3,011 3,090 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,266
99 89 100 123 204 258 325 432 758 387 331 330 318
CWIP 16 44 62 115 268 605 923 1,003 120 13 30 20 26
Investments 160 103 58 48 54 48 48 25 24 24 390 543 538
2,736 2,854 2,930 2,950 2,545 2,110 2,670 2,450 2,229 2,672 3,871 2,435 2,383
Total Assets 3,011 3,090 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,266

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Dec 2011 Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
322 294 267 341 138 232 475 411 491 595 820 488
368 -93 198 178 499 303 -107 -154 -63 408 -420 805
-392 -437 -490 -497 -638 -511 -307 -358 -428 -696 -524 -1,544
Net Cash Flow 298 -236 -25 22 -1 25 61 -102 0 307 -124 -251

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Dec 2011 Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 13 16 14 11 16 21 19 14 11 27 23 22
Inventory Days 133 94 108 89 155 111 147 131 135 153 144 128
Days Payable 80 78 88 74 96 72 148 109 99 131 156 122
Cash Conversion Cycle 66 32 34 26 75 61 18 37 47 49 11 27
Working Capital Days -51 -43 -46 -49 25 6 -91 -72 -35 -36 -95 -58
ROCE % 48% 50% 35% 41% 28% 22% 26% 31% 33% 37% 36% 36%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
1.59% 1.61% 1.72% 2.04% 2.18% 2.16% 2.17% 2.28% 2.28% 2.41% 2.50% 2.93%
10.85% 10.93% 10.83% 10.73% 10.73% 10.65% 10.54% 10.29% 10.31% 10.25% 10.01% 8.64%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01%
12.56% 12.46% 12.45% 12.23% 12.09% 12.19% 12.29% 12.43% 12.43% 12.35% 12.48% 13.42%
No. of Shareholders 1,19,9521,20,4761,21,4451,23,4801,10,1411,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,663

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents